At the end of six months, both treatments provided comparable outcomes for IPSS score decrease and quality of life score increase. However, Finasteride was able to significantly decrease prostate volume and PSA levels, while Permixon had little to no effect. Patients on finasteride had increased complaints of sexual dysfunction. The gene discussed is KLK3; the disease is sexual dysfunction.